-
Aptevo Therapeutics NASDAQ:APVO Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR™ platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer.
Location: 2401 4th Ave Ste 1050, Washington, 98121-3460, US | Website: aptevotherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-748K
Cash
8.066M
Avg Qtr Burn
-6.074M
Short % of Float
0.15%
Insider Ownership
0.04%
Institutional Own.
14.61%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
APVO436 (mipletamig) +/- Venetoclax + Azacitidine Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer | Phase 1/2 Data readout | |
ALG.APV-527 (4-1BB x 5T4) Details Cancer, Solid tumor/s, Pancreatic cancer, Non-small cell lung carcinoma, Breast cancer, Colorectal cancer | Phase 1 Data readout |